Biopharmaceutical
Topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in…
Read More
-Topline Data expected in the last week of July- Excerpt from the Press Release: SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) — Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced data…
Read More
Clinical trial collaboration supports global registrational Phase 3 study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib Agreement is supportive of the planned initiation of ZILO-301 in Q3 2022 and will also supply ibrutinib for the open-label companion study ZILO-302 Excerpt from the Press Release: SAN DIEGO, July 14, 2022…
Read More
Excerpt from the Press Release: SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ — Inmagene Biopharmaceuticals (“Inmagene“) and HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM:HCM; HKEX:13) announces today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody. The Phase I study…
Read More
AAVHSC16 Biodistribution Properties in Preclinical Models Demonstrated Potential for Systemic Delivery of Genetic Medicines to Brain, Heart and Muscle Excerpt from the Press Release: BEDFORD, Mass., July 05, 2022 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the peer-reviewed publication of data showing that AAVHSC16, one of the capsids…
Read More
Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China , July 3, 2022 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and other major diseases, announced that the first patient with moderate-to-severe active ulcerative colitis…
Read More
— Results Continue to Support that STAR-0215 is a Potent, Selective, and Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein — — STAR-0215 Demonstrates Rapid and Sustained Inhibition of Plasma Kallikrein After Subcutaneous Administration in Monkeys — Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and…
Read More
– REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease –– Losmapimod is an oral small molecule that has the potential to be the first therapy to treat FSHD, the second most common form of muscular dystrophy –– U.S. Food and Drug Administration (FDA) granted Fast Track Designation in 2021 –…
Read More
AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an initial focus on treatment-refractory MAC lung disease Phase 2/3 pivotal trial expected to support regulatory approval for treatment-refractory MAC lung disease; Plan to use LPAD pathway Excerpt from the Press Release:…
Read More Excellent safety, tolerability and pharmacokinetic profile Robust dose-dependent target engagement as measured by ex vivo IL-1β release assay Phase 2 trial planned in CAPS patients to efficiently establish clinical proof of concept Clinical update in Q3 from Phase 1 trial of VTX958, our oral, selective allosteric TYK2 inhibitor Excerpt from the Press Release: ENCINITAS, Calif., June…
Read More